Cargando…

Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and coronary artery disease (CAD) is the cardiac manifestation of metabolic syndrome. NAFLD is strongly linked to CAD and hepatic steatosis is an independent risk factor for CAD and cardiac morta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mehta, Rohini, Otgonsuren, Munkzhul, Younoszai, Zahra, Allawi, Hussain, Raybuck, Bryan, Younossi, Zobair
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964159/ https://www.ncbi.nlm.nih.gov/pubmed/27493762 http://dx.doi.org/10.1136/bmjgast-2016-000096

Ejemplares similares

Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease
por: Sayiner, Mehmet, et al.
Publicado: (2016)

Polymorphisms in the receptor for advanced glycation end-products (RAGE) gene and circulating RAGE levels as a susceptibility factor for non-alcoholic steatohepatitis (NASH)
por: Mehta, Rohini, et al.
Publicado: (2018)

Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH)
por: Mehta, Rohini, et al.
Publicado: (2016)

Expression of energy metabolism related genes in the gastric tissue of obese individuals with non-alcoholic fatty liver disease
por: Mehta, Rohini, et al.
Publicado: (2014)

Analysis of human leukocyte antigen allele polymorphism in patients with non alcoholic fatty liver disease
por: Karrar, Azza, et al.
Publicado: (2019)

Association of physical activity and fine motor performance in individuals with type 2 diabetes mellitus and/or non-alcoholic fatty liver disease
por: Weinstein, Ali A., et al.
Publicado: (2023)

Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome
por: Asfari, Mohammad Maysara, et al.
Publicado: (2020)

Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL)
por: Golabi, Pegah, et al.
Publicado: (2016)

Prevalence of frailty in patients with non-cirrhotic non-alcoholic fatty liver disease
por: Naimimohasses, Sara, et al.
Publicado: (2022)

Patient disease knowledge, attitudes and behaviours related to non-alcoholic fatty liver disease: a qualitative study
por: Tincopa, Monica A, et al.
Publicado: (2021)

Expression of NALPs in adipose and the fibrotic progression of non-alcoholic fatty liver disease in obese subjects
por: Mehta, Rohini, et al.
Publicado: (2014)

Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease
por: Nascimbeni, Fabio, et al.
Publicado: (2016)

Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease
por: Wood, Kayleigh L, et al.
Publicado: (2015)

Efficacy of dietary and physical activity intervention in non-alcoholic fatty liver disease: a systematic review
por: Kenneally, Susan, et al.
Publicado: (2017)

High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study
por: Duseja, Ajay, et al.
Publicado: (2019)

Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease
por: Hardy, Timothy, et al.
Publicado: (2017)

Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt
por: Tomah, Shaheen, et al.
Publicado: (2021)

Prevalence of non-alcoholic fatty liver disease in overweight and obese children seeking ambulatory healthcare in Nairobi, Kenya
por: Mburu, Anne Njeri, et al.
Publicado: (2023)

Pediatric Non-Alcoholic Fatty Liver Disease
por: Bush, Haley, et al.
Publicado: (2017)

Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma
por: Younossi, Zobair M., et al.
Publicado: (2021)

Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss
por: Hallsworth, Kate, et al.
Publicado: (2011)

RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease
por: Afonso, Marta B, et al.
Publicado: (2021)

Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

Prevalence, risk factors and metabolic profile of the non-obese and obese non-alcoholic fatty liver disease in a rural community of South Asia
por: Rahman, M Masudur, et al.
Publicado: (2020)

Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis
por: Sayiner, Mehmet, et al.
Publicado: (2017)

Hepatic sonic hedgehog protein expression measured by computer assisted morphometry significantly correlates with features of non-alcoholic steatohepatitis
por: Estep, Michael, et al.
Publicado: (2019)

Factors associated with engagement and adherence to a low-energy diet to promote 10% weight loss in patients with clinically significant non-alcoholic fatty liver disease
por: Scragg, Jadine, et al.
Publicado: (2021)

Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway
por: Li, Meng, et al.
Publicado: (2018)

Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia
por: Maev, Igor V, et al.
Publicado: (2020)

Mucosa-associated invariant T cells link intestinal immunity with antibacterial immune defects in alcoholic liver disease
por: Riva, Antonio, et al.
Publicado: (2018)

MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway
por: Wu, Heng, et al.
Publicado: (2016)

Cohort profile: the Trivandrum non-alcoholic fatty liver disease (NAFLD) cohort
por: Chalmers, Jane, et al.
Publicado: (2019)

Association of fatty liver disease with mortality outcomes in an Eastern Finland male cohort
por: Olubamwo, Olubunmi O, et al.
Publicado: (2019)

Influence of sex in alcohol‐related liver disease: Pre‐clinical and clinical settings
por: Bizzaro, Debora, et al.
Publicado: (2023)

Aspartate transaminase to platelet ratio index (APRI) but not FIB-5 or FIB-4 is accurate in ruling out significant fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) in an urban slum-dwelling population
por: Kolhe, Kailash Marotrao, et al.
Publicado: (2019)

Comparison of laboratory indices of non-alcoholic fatty liver disease for the detection of incipient kidney dysfunction
por: Choi, Jong Wook, et al.
Publicado: (2019)

Effects of sleep quality on non-alcoholic fatty liver disease: a cross-sectional survey
por: Takahashi, Atsushi, et al.
Publicado: (2020)

Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study
por: Tang, Xiaoping, et al.
Publicado: (2022)

Reliability and validity of the Chronic Liver Disease Questionnaire (CLDQ) in adults with non-alcoholic steatohepatitis (NASH)
por: Chawla, Kashmira S, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3ip65h5ev7qh9flu1554lvnu8p